1,721,176 research outputs found

    A mathematical model for the therapy of the HIV infection

    No full text
    In [17] it was introduced a model to describe the dynamics of the HIV infection when the patient is under chemotherapy (either RTI or PI). The main idea in [17] was to introduce the effectiveness of the drug as a dynamical variable. In this paper we pursue this idea starting from an analysis of the fitness of the virus during the therapy. We introduce an adaptive model in which the ability of the viruses to infect the target cells is related to the number of contacts between viruses and T–cells that have been inhibited by the drug. This approach is similar to the model proposed in [10] for a predator-prey system. However the biological interpretation is different here because in our context the adaptation of the virus is due to the development of resistant virus strains. We analyze different combination therapies with three antiviral drugs, which consist of reverse transcriptase inhibitor (RTI) and protease inhibitor (PI) and we show the possibility of very long latency periods, during which the viral load goes below the detectable level. These periods are followed by a rebound followed by the re–establishing of the conditions previous to the therapy. This dynamics is in good qualitative agreement with the available clinical data

    Pharmacokinetics and residue depletion of erythromycin in gilthead sea bream Sparus aurata L. after oral administration

    No full text
    Erythromycin (ERY) is an antibiotic effective against Streptococcus iniae, a microorganism responsible for significant losses in aquaculture. No data are available on the pharmacokinetics and residue depletion of ERY in sea bream. The aim of this study was thus to evaluate the pharmacokinetics of ERY in this species after a single oral administration at 75 mg kg-1 b.w. and to assess its residue depletion from tissues after prolonged treatment for 10 days. ERY was rapidly absorbed in sea bream (Cmax = 10.04 μg g-1 and Tmax=1 h), with a half-life of 9.35 h and an AUC0-24 of 56.81 (h μg mL-1). The data obtained and the evaluation of pharmacokinetic/pharmacodynamic parameters allowed us to hypothesize that dosage used in this study should be effective against S. iniae. A rapid reduction in erythromycin concentrations was observed in tissues, with the drug being detectable only during the first day post-treatment. In Europe, the use of ERY in aquaculture is allowed by off-label prescription with a withdrawal time of 500 °C day-1. The absence of ERY residues in tissues already at 24 h post-treatment suggests that ERY in sea bream should not pose human food safety issues
    corecore